Launch of new application enables global access to highly recognized solid tumor profiling assay BOSTON and ROLLE, Switzerland , Nov. 21, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, announced the global launch of MSK-IMPACT ® powered with SOPHiA DDMTM today from the Association for Molecular Pathology (AMP) Annual Meeting. This innovative solution provides organizations worldwide with the opportunity to benefit from Memorial Sloan Kettering Cancer Center (MSK)'s best-in-class comprehensive genomic profiling (CGP) application on the SOPHiA DDMTM Platform with high accuracy and efficiency.
"The launch of MSK-IMPACT ® powered with SOPHiA DDMTM is another major milestone in our journey to expand access to precision oncology globally and demonstrates our commitment to democratizing data-driven medicine," said Philippe Menu, M.D., PhD.
, Chief Product Officer and Chief Medical Officer, SOPHiA GENETICS . "Following the successful launch of MSK-ACCESS ® powered with SOPHiA DDMTM earlier this year, we are incredibly excited to further build on our excellent collaboration with MSK. Launching this application is a powerful step in our vision to decentralize access to advanced tumor profiling technologies, making these capabilities more widely available, especially in underserved populations.
" Kojo S. J. Elenitoba-Johnson, M.
D., Chair of the Department of Pathology and Lab Medicine at MSK, added, "We share a .
